Aktuellt
SENASTE
The recent CMS Medicare price of USD 322 is the last progress during a quarter of improved presence including Direct Bill, Hospital contracts, pharma partner projects and European distribution. Actual sales is in line with our expectations at SEK 2.5m and Biovica reiterates the outlook including higher DiviTum test volumes during calendar H1 2024. We are in the process of reviewing our Base Case (SEK 27, Bull SEK 60 and Bear SEK 5) reflecting an increased number of shares related to the ongoing rights issue.
LÄS MER
